Financhill
Back

Day One Biopharmaceuticals Quote, Financials, Valuation and Earnings

Buy
54

DAWN
Day One Biopharmaceuticals

Last Price:
16.18
Seasonality Move:
124.22%

7 Day Trial

ALL ACCESS PASS

$ 7

Day One Biopharmaceuticals Price Quote

$16.18
+0.01 (+0.94%)
(Updated: May 18, 2024 at 5:40 AM ET)

Day One Biopharmaceuticals Key Stats

Buy
54
Day One Biopharmaceuticals (DAWN) is a Buy

Day range:
$15.76 - $16.38
52-week range:
$9.67 - $18.07
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.72
P/B ratio:
4.76%

Volume:
421.2K
Avg. volume:
1.4M
1-year change:
22.59%
Market cap:
$1.4B
Revenue:
$0
EPS:
$-2.51

How Much Does Day One Biopharmaceuticals Make?

Data Unavailable

Is Day One Biopharmaceuticals Growing As A Company?

Data Unavailable

Day One Biopharmaceuticals Stock Price Performance

What Is Day One Biopharmaceuticals 52-Week High & Low?

Day One Biopharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Day One Biopharmaceuticals?

Is Day One Biopharmaceuticals Cash Flow Positive?

  • What Is DAWN Cash Flow From Operations?
    Cash flow from operations (TTM) is -$170.6M
  • What Is Day One Biopharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $162.9M
  • What Is Day One Biopharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $228.9M

Day One Biopharmaceuticals Return On Invested Capital

Data Unavailable

Day One Biopharmaceuticals Earnings Date & Stock Price

Day One Biopharmaceuticals Competitors

Day One Biopharmaceuticals Dividend Yield

Data Unavailable

Day One Biopharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -8.16%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 35.67
Upside from Last Price: 120.57%

Major Shareholders

  • How many DAWN shares are owned by institutional investors?
    108.6M DAWN shares are owned by institutional investors
  • How many DAWN shares are owned by insiders?
    2.4M DAWN shares are owned by insiders